Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 19 de 19
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Pharmacol Exp Ther ; 353(1): 213-33, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25665805

RESUMO

Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is currently limited to modulators of monoamine neurotransmitters and second-generation antipsychotics. Recently, glutamatergic approaches for the treatment of MDD have increasingly received attention, and preclinical research suggests that metabotropic glutamate receptor 5 (mGlu5) inhibitors have antidepressant-like properties. Basimglurant (2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine) is a novel mGlu5 negative allosteric modulator currently in phase 2 clinical development for MDD and fragile X syndrome. Here, the comprehensive preclinical pharmacological profile of basimglurant is presented with a focus on its therapeutic potential for MDD and drug-like properties. Basimglurant is a potent, selective, and safe mGlu5 inhibitor with good oral bioavailability and long half-life supportive of once-daily administration, good brain penetration, and high in vivo potency. It has antidepressant properties that are corroborated by its functional magnetic imaging profile as well as anxiolytic-like and antinociceptive features. In electroencephalography recordings, basimglurant shows wake-promoting effects followed by increased delta power during subsequent non-rapid eye movement sleep. In microdialysis studies, basimglurant had no effect on monoamine transmitter levels in the frontal cortex or nucleus accumbens except for a moderate increase of accumbal dopamine, which is in line with its lack of pharmacological activity on monoamine reuptake transporters. These data taken together, basimglurant has favorable drug-like properties, a differentiated molecular mechanism of action, and antidepressant-like features that suggest the possibility of also addressing important comorbidities of MDD including anxiety and pain as well as daytime sleepiness and apathy or lethargy.


Assuntos
Ansiolíticos/farmacologia , Antidepressivos/farmacologia , Depressão/tratamento farmacológico , Imidazóis/farmacologia , Piridinas/farmacologia , Receptor de Glutamato Metabotrópico 5/antagonistas & inibidores , Regulação Alostérica , Animais , Ansiolíticos/farmacocinética , Ansiolíticos/uso terapêutico , Antidepressivos/farmacocinética , Antidepressivos/uso terapêutico , Monoaminas Biogênicas/metabolismo , Encéfalo/metabolismo , Células Cultivadas , Cricetulus , Depressão/metabolismo , Depressão/psicologia , Agonismo Inverso de Drogas , Eletroencefalografia , Feminino , Imidazóis/farmacocinética , Imidazóis/uso terapêutico , Macaca fascicularis , Masculino , Camundongos , Dor/tratamento farmacológico , Dor/fisiopatologia , Piridinas/farmacocinética , Piridinas/uso terapêutico , Ensaio Radioligante , Ratos Sprague-Dawley , Ratos Wistar , Receptor de Glutamato Metabotrópico 5/metabolismo , Bexiga Urinária Hiperativa/tratamento farmacológico , Bexiga Urinária Hiperativa/fisiopatologia
2.
J Med Chem ; 58(3): 1358-71, 2015 Feb 12.
Artigo em Inglês | MEDLINE | ID: mdl-25565255

RESUMO

Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.


Assuntos
Depressão/tratamento farmacológico , Descoberta de Drogas , Síndrome do Cromossomo X Frágil/tratamento farmacológico , Imidazóis/farmacologia , Piridinas/farmacologia , Receptor de Glutamato Metabotrópico 5/antagonistas & inibidores , Regulação Alostérica/efeitos dos fármacos , Animais , Relação Dose-Resposta a Droga , Humanos , Imidazóis/síntese química , Imidazóis/química , Macaca mulatta , Masculino , Camundongos , Camundongos Endogâmicos , Estrutura Molecular , Piridinas/síntese química , Piridinas/química , Ratos , Ratos Sprague-Dawley , Ratos Wistar , Relação Estrutura-Atividade
3.
Acta Paediatr ; 103(11): 1130-5, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25060331

RESUMO

AIM: Studies have reported conflicting findings on whether different smells can reduce distress when infants undergo painful procedures. Our study assessed the impact of vanilla on infants' responses to a painful toe lance, including possible gender differences. METHODS: We measured the pain responses of 69 full-term infants - 34 girls and 35 boys - during toe lance, using two multidimensional scales - the Neonatal Facial Coding System and Behavioural Indicators of Infant Pain - together with crying duration and hand movements. Three sets of data were collected during baseline, toe lance and recovery, while the babies were exposed to the odour of vanilla (n = 39) or odourless water (n = 30). RESULTS: Pain responses increased significantly during toe lance, then declined during recovery. Crying duration correlated significantly with finger splaying/fisting and both pain scale scores, with boys displaying higher pain scores than girls. Vanilla had no impact on pain levels. CONCLUSION: Crying and finger splaying/fisting were observable responses that may be useful for screening pain or distress in healthy neonates. Increased pain reactions by boys may reflect higher irritability. Exposure to an unfamiliar odour did not have a calming effect on full-term neonates.


Assuntos
Aromaterapia , Manejo da Dor/métodos , Medição da Dor/métodos , Olfato , Feminino , Humanos , Recém-Nascido , Masculino , Estimulação Física , Fatores Sexuais , Nascimento a Termo
4.
Biochem Pharmacol ; 82(8): 891-903, 2011 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-21741954

RESUMO

A promising drug target currently under investigation to improve cognitive deficits in neuropsychiatric and neurological disorders is the neuronal nicotinic alpha7 acetylcholine receptor (α7nAChR). Improving cognitive impairments in diseases such as Alzheimer's (AD) and schizophrenia remains a large unmet medical need, and the α7nAChR has many properties that make it an attractive therapeutic target. The α7nAChR is a ligand gated ion channel that has particularly high permeability to Ca(2+) and is expressed in key brain regions involved in cognitive processes (e.g., hippocampus). The α7nAChRs are localized both pre-synaptically, where they can regulate neurotransmitter release, and post-synaptically where they can activate intracellular signaling cascades and influence downstream processes involved in learning and memory. In particular, activation of the α7nAChR with small molecule agonists enhances long-term potentiation, an in vitro model of synaptic plasticity, and improves performance across multiple cognitive domains in rodents, monkeys, and humans. Positive allosteric modulation of the α7nAChR offers an alternate approach to direct agonism that could prove to be particularly beneficial in certain disease populations where smoking nicotine is prevalent (e.g., schizophrenia) and could interfere with an orthosteric agonist approach. The current review focuses on the neurobiology of the α7nAChR, its role in cognition and the development status of some of the most promising molecules advancing for the treatment of cognitive dysfunction in disease.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Cognição/efeitos dos fármacos , Descoberta de Drogas/métodos , Receptores Nicotínicos/metabolismo , Esquizofrenia/tratamento farmacológico , Doença de Alzheimer/metabolismo , Animais , Comportamento Animal/efeitos dos fármacos , Cálcio/metabolismo , Colinérgicos/farmacologia , Colinérgicos/uso terapêutico , Modelos Animais de Doenças , Humanos , Memória/efeitos dos fármacos , Plasticidade Neuronal/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Receptores Nicotínicos/fisiologia , Esquizofrenia/metabolismo , Transmissão Sináptica/efeitos dos fármacos , Receptor Nicotínico de Acetilcolina alfa7
5.
Curr Top Med Chem ; 11(15): 1902-24, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-21470172

RESUMO

G protein-coupled receptors (GPCRs) share a common architecture consisting of seven transmembrane (TM) domains. Various lines of evidence suggest that this fold provides a generic binding pocket within the TM region for hosting agonists, antagonists, and allosteric modulators. Hence, an automated method was developed that allows a fast analysis and comparison of these generic ligand binding pockets across the entire GPCR family by providing the relevant information for all GPCRs in the same format. This methodology compiles amino acids lining the TM binding pocket including parts of the ECL2 loop in a so-called 1D ligand binding pocket vector and translates these 1D vectors in a second step into 3D receptor pharmacophore models. It aims to support various aspects of GPCR drug discovery in the pharmaceutical industry. Applications of pharmacophore similarity analysis of these 1D LPVs include definition of receptor subfamilies, prediction of species differences within subfamilies in regard to in vitro pharmacology and identification of nearest neighbors for GPCRs of interest to generate starting points for GPCR lead identification programs. These aspects of GPCR research are exemplified in the field of melanopsins, trace amine-associated receptors and somatostatin receptor subtype 5. In addition, it is demonstrated how 3D pharmacophore models of the LPVs can support the prediction of amino acids involved in ligand recognition, the understanding of mutational data in a 3D context and the elucidation of binding modes for GPCR ligands and their evaluation. Furthermore, guidance through 3D receptor pharmacophore modeling for the synthesis of subtype-specific GPCR ligands will be reported. Illustrative examples are taken from the GPCR family class C, metabotropic glutamate receptors 1 and 5 and sweet taste receptors, and from the GPCR class A, e.g. nicotinic acid and 5-hydroxytryptamine 5A receptor.


Assuntos
Descoberta de Drogas/métodos , Receptores Acoplados a Proteínas G/química , Sequência de Aminoácidos , Sítios de Ligação , Humanos , Ligantes , Modelos Moleculares , Dados de Sequência Molecular , Conformação Proteica , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores Acoplados a Proteínas G/metabolismo
6.
Bioorg Med Chem Lett ; 19(19): 5746-52, 2009 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-19726184

RESUMO

Through iterative design cycles we have discovered a number of novel new classes where the imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepine was deemed the most promising GABA(A) alpha5 inverse agonist class with potential for cognitive enhancement. This class combines a modest subtype binding selectivity with inverse agonism and has the most favourable molecular properties for further lead optimisation towards a central nervous system (CNS) acting medicine.


Assuntos
Benzodiazepinas/química , Nootrópicos/química , Receptores de GABA-A/metabolismo , Triazóis/química , Animais , Benzodiazepinas/síntese química , Benzodiazepinas/farmacologia , Descoberta de Drogas , Agonismo Inverso de Drogas , Agonistas de Receptores de GABA-A , Humanos , Nootrópicos/síntese química , Nootrópicos/farmacologia , Oócitos/efeitos dos fármacos , Triazóis/síntese química , Triazóis/farmacologia , Xenopus laevis
7.
Bioorg Med Chem Lett ; 18(9): 2916-9, 2008 May 01.
Artigo em Inglês | MEDLINE | ID: mdl-18406614

RESUMO

The (-)-(11R,2'S)-enantiomer of the antimalarial drug mefloquine has been found to be a reasonably potent and moderately selective adenosine A(2A) receptor antagonist. Further investigation of this compound has led to the discovery of a series of keto-aryl thieno[3,2-d]pyrimidine derivatives, which are potent and selective antagonists of the adenosine A(2A) receptor. These derivatives show selectivity against the A(1) receptor. Furthermore, some of these compounds have been shown to have in vivo activity in a commonly used model, suggesting the potential for the treatment of Parkinson's disease.


Assuntos
Antagonistas do Receptor A2 de Adenosina , Antimaláricos/uso terapêutico , Antiparkinsonianos/uso terapêutico , Transtornos Parkinsonianos/tratamento farmacológico , Pirimidinas/uso terapêutico , Antimaláricos/síntese química , Antiparkinsonianos/síntese química , Humanos , Modelos Químicos , Pirimidinas/síntese química , Estereoisomerismo , Relação Estrutura-Atividade
8.
ChemMedChem ; 3(1): 136-44, 2008 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-17994660

RESUMO

Detailed information on the metabolic fate of lead compounds can be a powerful tool for an informed approach to the stabilization of metabolically labile compounds in the lead optimization phase. The combination of high performance liquid chromatography (HPLC) with nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) has been used to give comprehensive structural data on metabolites of novel drugs in development. Recently, increased automation and the embedding of on-line solid-phase extraction (SPE) into a integrated LC-SPE-NMR-MS system have improved enormously the detection limits of this approach. The new technology platform allows the analysis of complex mixtures from microsome incubations, combining low material requirements with relatively high throughput. Such characteristics make it possible to thoroughly characterize metabolites of selected compounds at earlier phases along the path to lead identification and clinical candidate selection, thus providing outstanding guidance in the process of eliminating undesired metabolism and detecting active or potentially toxic metabolites. Such an approach was applied at the lead identification stage of a backup program on metabotropic glutamate receptor 5 (mGlu5) allosteric inhibition. The major metabolites of a lead 5-aminothiazole-4-carboxylic acid amide 1 were synthesized and screened, revealing significant in vitro activity and possible involvement in the overall pharmacodynamic behavior of 1. The information collected on the metabolism of the highly active compound 1 was pivotal to the synthesis of related compounds with improved microsomal stability.


Assuntos
Aminopiridinas/metabolismo , Microssomos Hepáticos/metabolismo , Preparações Farmacêuticas/metabolismo , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Tiazóis/metabolismo , Regulação Alostérica , Aminopiridinas/síntese química , Cromatografia Líquida de Alta Pressão/métodos , Humanos , Concentração Inibidora 50 , Espectroscopia de Ressonância Magnética/métodos , Espectrometria de Massas/métodos , Microssomos Hepáticos/química , Oxirredução , Preparações Farmacêuticas/síntese química , Receptor de Glutamato Metabotrópico 5 , Extração em Fase Sólida/métodos , Estereoisomerismo , Tiazóis/síntese química
9.
Acta Paediatr ; 96(3): 368-71, 2007 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-17407458

RESUMO

AIM: To assess the effects of exposure to the odour of mother's milk on breastfeeding behaviour of premature neonates. METHODS: Thirteen preterm infants born at 30-33 weeks gestational age were tested. Seven infants were randomly assigned to the milk-odour condition, 6 to the water-control condition. During week 35 post-conceptual age, each baby was exposed to the appropriate odour stimulus for 120 sec. on 5 consecutive days immediately prior to a breastfeeding attempt. The breastfeeding bout following the final odour exposure session, and a second breastfeeding session shortly before the baby left the hospital, were analysed. Babies were weighed before and after each feeding session. RESULTS: During each breastfeeding session, babies in the milk-odour condition displayed longer sucking bouts and more bursts composed of >7 sucking movements, and also consumed more milk than the Control infants. The time spent in the hospital was significantly less for the milk-odour condition (median = 43 days vs. 55.5 days for Controls). CONCLUSION: Brief exposure to the odour of mother's milk prior to early breastfeeding trials had a positive effect on sucking behaviour and milk ingestion of preterm babies, which in turn resulted in a shortened stay in the hospital.


Assuntos
Aleitamento Materno , Recém-Nascido Prematuro , Leite Humano , Odorantes , Comportamento de Sucção , Adulto , Feminino , Humanos , Recém-Nascido
10.
J Neurochem ; 98(2): 601-15, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16805850

RESUMO

Fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea], a clinically validated non-benzodiazepine anxiolytic, has been shown to be a potent and non-competitive metabotropic glutamate (mGlu)-5 receptor antagonist. In the present study, we have used the site-directed mutagenesis coupled with three-dimensional receptor-based pharmacophore modelling to elucidate the interacting mode of fenobam within the seven-transmembrane domain (7TMD) of mGlu5 receptor and its comparison with that of 2-methyl-6-(phenylethynyl)pyridine (MPEP), the prototype antagonist. The common residues involved in the recognition of MPEP and fenobam include Pro654(3.36), Tyr658(3.40), Thr780(6.44), Trp784(6.48), Phe787(6.51), Tyr791(6.55) and Ala809(7.47). The differentiating residues between both modulators' interacting modes are Arg647(3.29), Ser657(3.39) and Leu743(5.47). Our data suggest that these chemically unrelated mGlu5 antagonists act similarly, probing a functionally unique region of the 7TMD. Using [3H]inositol phosphates accumulation assay, we have also identified the critical residues involved in the inverse agonist effect of MPEP. The mutation W784(6.48)A completely blocked the inverse agonist activity of MPEP; two mutations F787(6.51)A and Y791(6.55)A, caused a drastic decrease in the MPEP inverse agonism. Furthermore, these three mutations led to an increased efficacy of quisqualate without having any effect on its potency. The fact that the residues Trp784(6.48) and Phe787(6.51) are essential equally in antagonism and inverse agonism effects emphasizes again the key role of these residues and the involvement of a common transmembrane network in receptor inactivation by MPEP.


Assuntos
Antagonistas de Aminoácidos Excitatórios/farmacologia , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/agonistas , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Sítios de Ligação , Cálcio/metabolismo , Linhagem Celular , Membrana Celular/metabolismo , Células Cultivadas , Fluorometria , Humanos , Imidazóis/metabolismo , Fosfatos de Inositol/metabolismo , Modelos Moleculares , Mutação/fisiologia , Plasmídeos , Ácido Quisquálico/antagonistas & inibidores , Ácido Quisquálico/farmacologia , Receptor de Glutamato Metabotrópico 5 , Tiazóis/farmacologia
11.
Bioorg Med Chem Lett ; 16(7): 1892-7, 2006 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-16439120

RESUMO

Optimisation of affinity, chemical stability, metabolic stability and solubility led from a chemically labile HTS hit 1 to mGlu5 receptor antagonists (24-26) with high affinity for the allosteric MPEP binding site, improved microsomal metabolic stability and anxiolytic-like activity in vivo as assessed by the Vogel conflict drinking test.


Assuntos
Antagonistas de Aminoácidos Excitatórios/farmacologia , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Administração Oral , Antagonistas de Aminoácidos Excitatórios/administração & dosagem , Antagonistas de Aminoácidos Excitatórios/química , Piridinas/administração & dosagem , Piridinas/química
12.
Eur J Pharmacol ; 529(1-3): 95-104, 2006 Jan 04.
Artigo em Inglês | MEDLINE | ID: mdl-16352303

RESUMO

Several mutations in the seven-transmembrane region of rat metabotropic glutamate 5 (rmGlu5) receptors were produced by site-directed mutagenesis and expressed in CHO cells. Using functional intracellular calcium ([Ca(2+)](i)) mobilisation, we identified amino acids implicated in the positive allosteric modulation of quisqualate-induced response by 3,3'-difluorobenzaldazine (DFB). Human and rat mGlu5 receptors displayed a higher potency and a higher efficacy in the presence of DFB. Mutant receptors S657(3.39)C, T780(6.44)A and M801(7.39)T disrupted the DFB-mediated increase in functional response. DFB-induced increase in potency was abolished in mutant receptors N733(45.51)A, Y791(6.55)A, A809(7.47)V, P654(3.36)S/S657(3.39)C and P654(3.36)S/S657(3.39)C/L743(5.47)V without affecting the enhancement of efficacy observed in wild type receptors. Mutations at positions Leu-743(5.47) and Trp-784(6.48) resulted in significantly larger DFB-induced potentiation of EC(50) and E(max) values than in wild type receptors. DFB-mediated increase of efficacy was abolished and EC(50) values were right-shifted in mutant receptor F787A, resulting in DFB acting as a weak partial antagonist at this mutant receptor. Based on these findings, we constructed a homology model concluding that six key residues in transmembranes 3, 5, 6 and 7 are necessary for the allosteric modulation of rmGlu5a receptor by DFB. The model confirms an overlapping but distinct binding site to 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and in particular emphasises the key role of W784 in transmembrane (TM) 6 for controlling the receptor's activation state.


Assuntos
Hidrazinas/farmacologia , Receptores de Glutamato Metabotrópico/genética , Receptores de Glutamato Metabotrópico/metabolismo , Regulação Alostérica , Sequência de Aminoácidos , Animais , Sítios de Ligação , Células CHO , Cálcio/metabolismo , Cricetinae , Cricetulus , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Mutação Puntual , Ratos , Receptor de Glutamato Metabotrópico 5 , Alinhamento de Sequência
13.
J Exp Biol ; 208(Pt 23): 4419-26, 2005 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-16339862

RESUMO

Most ungulates are gregarious species and outside the mating season are typically observed in single-sex groups. However little is known about the mechanisms underlying social segregation between sexes. We investigated the effect of conspecific attraction on individual spacing between unrestrained merino sheep Ovis aries and confined conspecifics. We considered differences between males and females and whether attractiveness of the confined conspecifics depends on their sex. A series of binary choice experiments was conducted in a large outdoor arena, located in pastures. One or two stimulus animals were placed in small individual cages (1.5 m x 1 m) on opposite sides of the arena. Sheep were tested with one fixed peer of the same or opposite sex vs an empty cage, and with two fixed peers of either the same sex as themselves, or one male and one female. Sheep in a control condition were exposed to two empty cages. In all of the test conditions, confined sheep were highly attractive. Males were more attracted by single stimulus peers of the same than the opposite sex, whereas females did not display such a preference. Sheep confronted with two restrained conspecifics tended to remain between the stimuli. This also occurred when the stimuli were of opposite sex, although the males tended to be located nearer the same-sex peer. Our findings can explain the strong aggregative behaviour of merino sheep, but also the social segregation previously observed in a mixed-sex group through higher attraction for same-sex than opposite-sex peers in males.


Assuntos
Caracteres Sexuais , Comportamento Sexual Animal/fisiologia , Ovinos/fisiologia , Comportamento Social , Comportamento Espacial/fisiologia , Análise de Variância , Animais , Feminino , Masculino
14.
J Chem Inf Model ; 45(5): 1324-36, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16180909

RESUMO

G protein-coupled receptors (GPCRs) share a common architecture consisting of seven transmembrane (TM) domains. Various lines of evidence suggest that this fold provides a generic binding pocket within the TM region for hosting agonists, antagonists, and allosteric modulators. Here, a comprehensive and automated method allowing fast analysis and comparison of these putative binding pockets across the entire GPCR family is presented. The method relies on a robust alignment algorithm based on conservation indices, focusing on pharmacophore-like relationships between amino acids. Analysis of conservation patterns across the GPCR family and alignment to the rhodopsin X-ray structure allows the extraction of the amino acids lining the TM binding pocket in a so-called ligand binding pocket vector (LPV). In a second step, LPVs are translated to simple 3D receptor pharmacophore models, where each amino acid is represented by a single spherical pharmacophore feature and all atomic detail is omitted. Applications of the method include the assessment of selectivity issues, support of mutagenesis studies, and the derivation of rules for focused screening to identify chemical starting points in early drug discovery projects. Because of the coarseness of this 3D receptor pharmacophore model, however, meaningful scoring and ranking procedures of large sets of molecules are not justified. The LPV analysis of the trace amine-associated receptor family and its experimental validation is discussed as an example. The value of the 3D receptor model is demonstrated for a class C GPCR family, the metabotropic glutamate receptors.


Assuntos
Membrana Celular/metabolismo , Receptores Acoplados a Proteínas G/química , Receptores Acoplados a Proteínas G/metabolismo , Sequência de Aminoácidos , Animais , Automação , Sítios de Ligação , Dados de Sequência Molecular , Filogenia , Conformação Proteica , Receptores Acoplados a Proteínas G/antagonistas & inibidores , Receptores Acoplados a Proteínas G/genética , Relação Estrutura-Atividade
15.
J Pharmacol Exp Ther ; 315(2): 711-21, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16040814

RESUMO

Fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] is an atypical anxiolytic agent with unknown molecular target that has previously been demonstrated both in rodents and human to exert anxiolytic activity. Here, we report that fenobam is a selective and potent metabotropic glutamate (mGlu)5 receptor antagonist acting at an allosteric modulatory site shared with 2-methyl-6-phenylethynyl-pyridine (MPEP), the protypical selective mGlu5 receptor antagonist. Fenobam inhibited quisqualate-evoked intracellular calcium response mediated by human mGlu5 receptor with IC(50) = 58 +/- 2 nM. It acted in a noncompetitive manner, similar to MPEP and demonstrated inverse agonist properties, blocking 66% of the mGlu5 receptor basal activity (in an over expressed cell line) with an IC(50) = 84 +/- 13 nM. [(3)H]Fenobam bound to rat and human recombinant receptors with K(d) values of 54 +/- 6 and 31 +/- 4 nM, respectively. MPEP inhibited [(3)H]fenobam binding to human mGlu5 receptors with a K(i) value of 6.7 +/- 0.7 nM, indicating a common binding site shared by both allosteric antagonists. Fenobam exhibits anxiolytic activity in the stress-induced hyperthermia model, Vogel conflict test, Geller-Seifter conflict test, and conditioned emotional response with a minimum effective dose of 10 to 30 mg/kg p.o. Furthermore, fenobam is devoid of GABAergic activity, confirming previous reports that fenobam acts by a mechanism distinct from benzodiazepines. The non-GABAergic activity of fenobam, coupled with its robust anxiolytic activity and reported efficacy in human in a double blind placebo-controlled trial, supports the potential of developing mGlu5 receptor antagonists with an improved therapeutic window over benzodiazepines as novel anxiolytic agents.


Assuntos
Ansiolíticos/farmacologia , Imidazóis/farmacologia , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/agonistas , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Animais , Células CHO , Linhagem Celular , Células Cultivadas , Condicionamento Operante/efeitos dos fármacos , Conflito Psicológico , Cricetinae , AMP Cíclico/metabolismo , DNA Complementar/biossíntese , DNA Complementar/genética , Comportamento de Ingestão de Líquido/efeitos dos fármacos , Emoções/efeitos dos fármacos , Febre/fisiopatologia , Guanosina 5'-O-(3-Tiotrifosfato)/metabolismo , Humanos , Fosfatos de Inositol/metabolismo , Masculino , Camundongos , Plasmídeos/genética , Ratos , Ratos Sprague-Dawley , Receptor de Glutamato Metabotrópico 5 , Estresse Fisiológico/fisiopatologia
16.
Br J Pharmacol ; 144(8): 1118-25, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15700023

RESUMO

1. Several combinations of cysteine to serine mutations at positions 57, 93, 99 and 129 in the extracellular N-terminal domain of human metabotropic 5a (hmGlu5a) receptors were produced and expressed in HEK293 cells. Quisqualic acid-induced intracellular calcium ([Ca(2+)](i)) mobilization and inositol phosphates (IP) accumulation revealed an apparent increased efficacy and decreased potency for hmGlu5a mutants C57S, C99S and C57/99S, as well as a total loss of function for the mutant C57/93/99/129S. 2. [(3)H]Quisqualate saturation analysis revealed mutants C57S, C99S, C57/99S and the tetramutant C57/93/99/129S to have unchanged K(D) but reduced B(max) values. [(3)H]MPEP saturation analysis on the same membrane preparations revealed no difference in K(D) for any mutant, but a decrease in B(max) value for the C57/93/99/129S receptor. 3. Inverse agonism of MPEP at hmGlu5a receptors was partially reduced by mutation C57S, significantly reduced by C99S and C57/99S mutations and totally abolished in the tetramutant. 4. We confirmed the surface expression of all the mutated receptors using [(3)H]MPEP binding analysis on whole cells. However, B(max) values were increased for mutant C57S, C99S, and C57/99S but decreased in the C57/93/99/129S receptor. 5. The 24 h preincubation of cells expressing hmGlu5a receptors with 1 muM MPEP followed by extensive washing dramatically increased the wild-type receptor efficacy to quisqualate, to the same levels seen with C57/99S receptors. MPEP preincubation did not affect C57/99S function. 6. We conclude that cysteines 57 and 99 are key residues necessary for modulating hmGlu5a receptor function.


Assuntos
Cisteína/metabolismo , Receptores de Glutamato Metabotrópico/metabolismo , Linhagem Celular , Cisteína/genética , Relação Dose-Resposta a Droga , Humanos , Mutagênese Sítio-Dirigida , Ligação Proteica/fisiologia , Receptor de Glutamato Metabotrópico 5 , Receptores de Glutamato Metabotrópico/genética
17.
Mol Pharmacol ; 64(4): 823-32, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14500738

RESUMO

Metabotropic glutamate (mGlu) 5 is a G-protein-coupled metabotropic glutamate receptor that plays an important role as a modulator of synaptic plasticity, ion channel activity, and excitotoxicity. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) is a highly potent, noncompetitive, selective, and systemically active antagonist of mGlu5 receptors. It binds to a novel allosteric site that resides within the seven-transmembrane domain of mGlu5 receptors. Using site-directed mutagenesis, [3H]MPEP binding, a functional Ca2+ mobilization assay, and rhodopsin-based homology modeling, we identified eight residues (Pro-6543.36, Tyr-6583.40, Leu-7435.47, Thr-7806.44, Trp-7846.48, Phe-7876.51, Tyr-7916.55, and Ala-8097.47) that are crucial for MPEP-binding to rat mGlu5 receptors. Four mutations, Y6583.40V, W7846.48A, F7876.51A, and A8097.47V, caused complete loss of [3H]MPEP binding and also blocked the MPEP-mediated inhibition of quisqualate-induced intracellular Ca2+ mobilization. To visualize these experimental findings, we have constructed a homology model based on the X-ray crystal of bovine rhodopsin and have suggested a possible binding mode of MPEP. We propose that MPEP via its interactions with a network of the aromatic residues including Phe-6583.40 in transmembrane (TM) 3 helix and Trp-7986.48, Phe-7876.51, and Tyr-7916.55 in TM6 helix prevents the movement of TM6 helix relative to TM3 helix, a step that is required for receptor activation, and consequently stabilizes the inactive conformation of mGlu5 receptor. In the TM6 region, we observed a striking similarity between the critical residues involved in MPEP-binding site with those of previously identified as 1-ethyl-2-methyl-6-oxo-4-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydropyrimidine-5-carbonitrile-binding pocket of mGlu1, pointing to a common mechanism of inhibition shared by both antagonists.


Assuntos
Antagonistas de Aminoácidos Excitatórios/farmacologia , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Sítio Alostérico , Sequência de Aminoácidos , Animais , Sítios de Ligação , Cálcio/metabolismo , Células Cultivadas , Agonistas de Aminoácidos Excitatórios/farmacologia , Humanos , Modelos Moleculares , Conformação Molecular , Dados de Sequência Molecular , Mutação Puntual , Estrutura Terciária de Proteína , Ácido Quisquálico/farmacologia , Ratos , Receptor de Glutamato Metabotrópico 5 , Receptores de Glutamato Metabotrópico/química , Receptores de Glutamato Metabotrópico/genética , Rodopsina/química , Homologia de Sequência de Aminoácidos , Trítio
18.
J Med Chem ; 46(7): 1273-6, 2003 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-12646038

RESUMO

A small series of aryl pyridyl sulfones has been prepared and investigated for its 5-HT(6) receptor binding properties. Thereof, pyrrolidinyl derivative 11 proved to be a very potent (pK(i) 9) and selective 5-HT(6) receptor antagonist. By means of in vivo microdialysis in the frontal cortex and a passive avoidance paradigm, where 11 reversed a scopolamine induced retention deficit, a functional correlation between 5-HT(6) receptors and cholinergic neurotransmission could be shown, supporting the therapeutic potential of 5-HT(6) receptors in the treatment of cognitive deficits.


Assuntos
Acetilcolina/metabolismo , Lobo Frontal/efeitos dos fármacos , Piridinas/síntese química , Receptores de Serotonina/efeitos dos fármacos , Antagonistas da Serotonina/síntese química , Sulfonas/síntese química , Administração Oral , Animais , Aprendizagem da Esquiva/efeitos dos fármacos , Disponibilidade Biológica , Barreira Hematoencefálica , Linhagem Celular , Lobo Frontal/metabolismo , Meia-Vida , Humanos , Técnicas In Vitro , Injeções Intravenosas , Microdiálise , Microssomos Hepáticos/metabolismo , Piridinas/química , Piridinas/farmacologia , Ratos , Receptores de Serotonina/fisiologia , Antagonistas da Serotonina/química , Antagonistas da Serotonina/farmacologia , Sulfonas/química , Sulfonas/farmacologia , Distribuição Tecidual
19.
Behav Neurosci ; 116(2): 206-11, 2002 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11996306

RESUMO

Thirty-one neonates delivered by cesarean section were exposed to an odor for 30 min shortly after birth. Fifteen births had uterine labor contractions before delivery; 16 were without contractions. All babies were later tested (median age = 80 hr) for their responses to the familiar exposure odor and a novel odor presented on either side of the face. Overall, the babies spent more time turned toward the exposure odor than toward the novel scent. Babies in the labor condition, but not those bom without labor, displayed a significant preference for the exposure odor. Norepinephrine (NE) levels were higher in babies who oriented preferentially toward the exposure odor. Brief exposure immediately after birth is sufficient for the development of olfactory learning. Heightened learning by neonates from births with contractions may reflect locus coeruleus and NE activation. Olfactory learning may therefore be particularly efficient shortly after birth.


Assuntos
Trabalho de Parto , Aprendizagem , Período Pós-Parto , Olfato/fisiologia , Sinais (Psicologia) , Feminino , Humanos , Recém-Nascido , Masculino , Norepinefrina/metabolismo , Gravidez , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...